T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 4, 2018

Primary Completion Date

December 20, 2023

Study Completion Date

December 20, 2023

Conditions

COL6A3 PositiveHLA-A*0201 Positive Cells PresentPRAME PositiveRecurrent Ovarian Carcinoma

Interventions

BIOLOGICAL

Aldesleukin

Given IV

DRUG

CD8-Positive T-Lymphocyte

Given IV

DRUG

Cyclophosphamide

Given IV

PROCEDURE

Leukapheresis

Undergo leukapheresis

BIOLOGICAL

Utomilumab

Given IV

Trial Locations (1)

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT03318900 - T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer | Biotech Hunter | Biotech Hunter